Ultragenyx Reports Q2 2026 Financial Results (8-K)

What Happened
On August 4, 2026, Ultragenyx Pharmaceutical Inc. announced and furnished a press release reporting its financial results for the three months ended June 30, 2026. The company filed this information on Form 8-K under Item 2.02 (Results of Operations and Financial Condition) and included the press release as Exhibit 99.1. The report was signed by Howard Horn, Executive Vice President and Chief Financial Officer, Corporate Strategy.

Key Details

• Filing date: August 4, 2026 (Form 8-K).
• Period covered: three months ended June 30, 2026 (Q2 2026).
• Press release furnished as Exhibit 99.1; cover page provided in Inline XBRL (Exhibit 104).
• 8-K executed by Howard Horn, EVP & CFO (Corporate Strategy).

Why It Matters
This 8-K signals that Ultragenyx has publicly released its latest quarterly results; investors should review the furnished press release (Exhibit 99.1) for revenue, profit/loss, cash position, guidance and any management commentary. Those figures and any guidance typically influence short-term trading and longer-term valuation, so retail investors may want to read the press release and watch related investor communications (earnings release, webcast, or SEC filings) for the full financial details.